Houston, TX - (NewMediaWire) - November 29, 2021 - ChinaInfrastructure Construction Corp (OTC:CHNC)
From my desk…
It is withgreat pleasure that I take a moment out of my day to write this letter torespond and/or clarify one of the most frequent questions that our shareholdershave submitted requesting information about. Our shareholders have shown interestin further exploring and/or understanding the portion under which we conduct ourclinical trials and our development of these projects.
AlphaResearch Institute, one of CHNC’s branches and a Houston-based researchfacility, is currently active and continues to become one of the top researchcenters in Houston. Several clinical trials take place in Alpha on a dailybasis, these are research studies in which people volunteer to find newtreatments and ways to improve public health problems, through proceduresmonitored by doctors and health professionals bound to FDA’s guidelines.
Furthermore,Alpha’s team is responsible for planning, setting up, and executing day-to-daymanagement of the contracted clinical trials. Every single study is different,so to supply these services, our multidisciplinary team must meticulously read,analyze, comprehend, apply and work under the rules and terms of variousprotocols. These protocols act as a baseline for establishing our targetpatient audience so that the results of these studies are adapted to thespecific research needs of our sponsors, guaranteeing patient safety and theproper development of each procedure.
Our researchcenter has a highly professional relationship with its sponsors marked byconfidentiality, which is why we cannot answer some of the questions anddisclose certain information that could harm our company or others as most of theguidelines belong to the intellectual property of our sponsors.
However, weare glad to share the information we can disclose. At present, Alpha has 15clinical trials available and open for patient recruitment. These studiesinclude: Children's biological sample collection, Rheumatoid Arthritis, Activeinfection (STD), Chronic Diarrhea, Adult biological sample collection, Diabeticretinopathy, Celiac disease, Suspected infection, and five different cancerstudies (which once more we cannot name due to our confidentiality agreements),Chronic Constipation, metabolic disease studies, and Covid-19, all under thesupervision and care of our Clinical Trials Medical Director, Dr. Deepika Deol.
Moreover, wecontinue to grow and expand by recruiting more doctors (PrincipleInvestigators), recruitment teams, and marketing strategies, to allow for thesmooth development of the clinical trials. Alpha’s team has worked non-stop toimprove many processes and expects to acquire alliances with new sponsors inthe coming year, so as to expand its clinical trial offer and improve its relationshipwith its community and patients under the direction of Dr. Harpran, Director ofClinical Trials Recruitment.
CHNC, as apart of the research industry, does not only benefit from its well-knownprofitability and opportunities, but also works on giving back to itscommunity, providing the necessary tools and human talent to help develop newtechnologies, treatments, and solutions to improve the quality of life ofpatients around the world. It is our grain of sand that works in great synergy withour brand’s values and mission.
Conclusively,as usual, I would like to take this opportunity to thank our directors andshareholders, but equally important, each and every one of our staff membersthat work tirelessly to meet deadlines and innovate our products on a dailybasis to create new revenue generating centers, as well as the highest possiblereturn for our shareholders.
All my best,
Dante Picazo
CEO of CHNC
To learnmore visit: https://www.chnc-hdh.com/
Safe HarborStatement
Theinformation posted in this release may contain forward-looking statementswithin the meaning of the Private Securities Litigation Reform Act of 1995. Youcan identify these statements by use of the words "may,""will," "should," "plans," "explores,""expects," "anticipates," "continue,""estimate," "projects," "intends," and similarphrases. Forward-looking statements involve risks and uncertainties that couldcause actual results to differ from those projected or anticipated. These risksand uncertainties include, but are not limited to, general economic andbusiness conditions, effects of geopolitical conditions, competition, changesin technology and methods of marketing, and various other factors beyond thecompany's control.
For moreinformation contact us at:
info@pharmacologyuniversity.com
817/528-2475 for English
214/733-0868 for Spanish
View the original release on www.newmediawire.com
China Infrastructure Construction Corp.